Condition
Neuroendocrine Cancer clinical trials and research
As of November 12, 2026, Find a Trial lists 6 Neuroendocrine Cancer clinical trials that are recruiting, at sites in 5 countries (most in China (3), United States (2), Australia (1)). By phase: Phase 1 (3), Phase 1/2 (1), Phase 2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 6Clinical trials
- 5Countries
Newest Neuroendocrine Cancer clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Armored DLL3-SAVVYZ-IL18 CAR T cells for DLL3+ cancers | Phase 1 | Basking Ridge, New Jersey and 6 other locations | Recruiting | Aug 24, 2026 |
| TLN-499 plus venetoclax in relapsed or refractory solid tumors | Phase 1 | Camperdown, New South Wales and 2 other locations | Recruiting | Jul 20, 2026 |
| DLL3-targeted PET/CT for detecting neuroendocrine carcinoma | — | Xiamen, Fujian | Recruiting | Mar 9, 2026 |
| BL-M14D1 for people with advanced small cell lung cancer and other neuroendocrine tumors. | Phase 1 | Huntsville, Alabama and 30 other locations | Recruiting | Jul 23, 2025 |
| Using Ivocizumab to treat various advanced rare tumors | Phase 2 | Shanghai, Shanghai Municipality | Recruiting | Nov 12, 2024 |
| Testing ZG006 for advanced small cell lung cancer and neuroendocrine carcinoma | Phase 1/2 | Shanghai, Shanghai Municipality | Recruiting | Feb 28, 2024 |
All recruiting trials (6)
-
Armored DLL3-SAVVYZ-IL18 CAR T cells for DLL3+ cancers
Aims to see if DLL3-SAVVYZ-IL18 CAR T cells can be safely given to people with DLL3-positive cancers, including certain small cell lung cancers and other neuroendocrine tumors.
-
TLN-499 plus venetoclax in relapsed or refractory solid tumors
Doctors are testing whether TLN-499 added to venetoclax can help patients with relapsed or refractory solid tumors, including SCLC and certain neuroendocrine cancers.
-
DLL3-targeted PET/CT for detecting neuroendocrine carcinoma
We are testing a DLL3-targeted PET/CT scan to see if it better finds tumors in adults with suspected or confirmed neuroendocrine carcinoma.
-
BL-M14D1 for people with advanced small cell lung cancer and other neuroendocrine tumors.
This trial will try BL-M14D1 in adults with locally advanced or metastatic small cell lung cancer or other high-grade neuroendocrine tumors to see if it is safe and helps control the cancer after standard treatments have failed.
-
Using Ivocizumab to treat various advanced rare tumors
This study is testing if a new treatment called Ivocizumab can help people with different types of advanced rare tumors feel better and live longer.
-
Testing ZG006 for advanced small cell lung cancer and neuroendocrine carcinoma
This study is testing a new treatment called ZG006 to see if it is safe and effective for people with advanced small cell lung cancer and neuroendocrine carcinoma.
Related topics
Quick answers
How many Neuroendocrine Cancer clinical trials are recruiting right now?
6, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 5 countries. The most sites are in China (3 trials), United States (2 trials), Australia (1 trial), Georgia (1 trial), Ukraine (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 3, Phase 1/2: 1, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.